We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS).
- Authors
Shitara, Kohei; Doi, Toshihiko; Hosaka, Hisashi; Thuss-Patience, Peter; Santoro, Armando; Longo, Federico; Ozyilkan, Ozgur; Cicin, Irfan; Park, David; Zaanan, Aziz; Pericay, Carles; Özgüroğlu, Mustafa; Alsina, Maria; Makris, Lukas; Benhadji, Karim A.; Ilson, David H.
- Abstract
Background: Trifluridine and tipiracil (FTD/TPI) demonstrated survival benefit vs placebo and manageable safety in previously treated patients with metastatic gastric/gastroesophageal junction cancer (mGC/GEJC) in the randomized, placebo-controlled, phase 3 TAGS study. This subgroup analysis of TAGS examined efficacy/safety outcomes by age. Methods: In TAGS, patients with mGC/GEJC and ≥ 2 prior therapies were randomized (2:1) to receive FTD/TPI 35 mg/m2 or placebo, plus best supportive care. A preplanned subgroup analysis was performed to evaluate efficacy and safety outcomes in patients aged < 65, ≥ 65, and ≥ 75 years. Results: Among 507 randomized patients (n = 337 FTD/TPI; n = 170 placebo), 55%, 45%, and 14% were aged < 65, ≥ 65, and ≥ 75 years, respectively. Overall survival hazard ratios for FTD/TPI vs placebo were 0.67 (95% CI 0.51–0.89), 0.73 (95% CI 0.52–1.02), and 0.67 (95% CI 0.33–1.37) in patients aged < 65, ≥ 65, and ≥ 75 years, respectively. Regardless of age, patients receiving FTD/TPI experienced improved progression-free survival and stayed longer on treatment than those receiving placebo. Among FTD/TPI-treated patients, frequencies of any-cause grade ≥ 3 adverse events (AEs) were similar across age subgroups (80% each), although grade ≥ 3 neutropenia was more frequent in older patients [40% (≥ 65 and ≥ 75 years); 29% (< 65 years)]; AE-related discontinuation rates did not increase with age [14% (< 65 years), 12% (≥ 65 years), and 12% (≥ 75 years)]. Conclusions: The results of this subgroup analysis show the efficacy and tolerability of FTD/TPI treatment regardless of age in patients with mGC/GEJC who had received 2 or more prior treatments.
- Subjects
ESOPHAGOGASTRIC junction; OLDER patients; SUBGROUP analysis (Experimental design); OVERALL survival; PROGRESSION-free survival; GASTRIC bypass
- Publication
Gastric Cancer, 2022, Vol 25, Issue 3, p586
- ISSN
1436-3291
- Publication type
Article
- DOI
10.1007/s10120-021-01271-9